Why Viking Therapeutics Stock Skyrocketed on Tuesday
The biotech's obesity drug candidate could make it easier for people who have recently lost weight to keep it off.
Overview
Shares of Viking Therapeutics (NASDAQ: VKTX) surged on Tuesday after the biopharmaceutical specialist announced encouraging clinical trial results for its experimental weight loss drug.
Image source: Getty Images.
People receiving weekly doses of Viking's investigational obesity drug, VK2735, lost 16% to 19% of their bodyweight after 21 weeks, compared with roughly 0% for placebo.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.